

02nd February, 2024

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2023

The Presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2023 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a



Q3 FY 2023-24

Revenues: Summary



Revenue: Summary

| Revenues (Rs cr) | Q3 FY24 | Q3 FY23 | Gr% |
|------------------|---------|---------|-----|
| India | 1,415 | 1,259 | 12% |
| United States | 274 | 291 | -6% |
| Germany | 270 | 241 | 12% |
| Brazil | 312 | 248 | 26% |
| Others | 461 | 451 | 2% |
| Total | 2,732 | 2,491 | 10% |

